NCT05094336: An ongoing trial by Amgen
This trial is ongoing. It must report results 1 year, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05094336 |
|---|---|
| Title | A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 1, 2022 |
| Completion date | May 27, 2026 |
| Required reporting date | May 27, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 17, 2026 |
| Days late | None |